NUCLEOLARON
Toagosei Co., Ltd.
Application Filed: 2022-06-30
Trademark Application Details
Mark For: NUCLEOLARON™ trademark registration is intended to cover the category of
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
| Research |
OneLook
Acronym Finder
|
| Serial Number | 97482649 |
| Mark Literal Elements | NUCLEOLARON |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | Trademark |
| Current Location | NEW APPLICATION PROCESSING 2022-07-04 |
| Basis | 44(e) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | No |
| Filed ITU | No |
| 44D Filed | No |
| 44E Current | Yes |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Domestic Representative | Boris Umansky |
| Attorney Name | Boris Umansky |
| Attorney Docket Number | 3T22783018 |
Timeline
| 2022-05-24 | Trademark Registered |
| 2022-06-30 | Application Filed |
| 2022-07-04 | Location: NEW APPLICATION PROCESSING |
| 2022-07-04 | Status: Live/Pending |
| 2022-07-04 | Status: New application will be assigned to an examining attorney approximately 6 months after filing date. |
| 2022-07-04 | Transaction Date |
Trademark Parties (Applicants & Owners)
| Party: |  TOAGOSEI CO., LTD. |
| Address | 1-14-1, NISHI-SHINBASHI MINATO-KU, TOKYO JAPAN 105-8419 |
| Legal Entity Type | Corporation |
| Legal Entity State | JAPAN |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 1 |
| U.S. Codes: | 001,005,006,010,026,046 |
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical or veterinary purposes; Medicinal preparations and substances for the treatment of muscular dystrophy, muscle diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, cancer, heart diseases and disorders, and brain diseases and disorders; Pharmaceutical preparations and substances for the treatment of muscular dystrophy, muscle diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, cancer, heart diseases and disorders, and brain diseases and disorders; Pharmaceuticals for the treatment of muscular dystrophy, muscle diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, cancer, heart diseases and disorders, and brain diseases and disorders; Medicines for the treatment of muscular dystrophy, muscle diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, cancer, heart diseases and disorders, and brain diseases and disorders; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Medicinal preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals |
| GS0051 | Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical or veterinary purposes; Medicinal preparations for the treatment of muscular dystrophy, muscle diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, cancer, heart diseases and disorders, and brain diseases and disorders; Pharmaceutical preparations for the treatment of muscular dystrophy, muscle diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, cancer, heart diseases and disorders, and brain diseases and disorders; Pharmaceuticals for the treatment of muscular dystrophy, muscle diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, cancer, heart diseases and disorders, and brain diseases and disorders; Medicines for the treatment of muscular dystrophy, muscle diseases and disorders, neurological diseases and disorders, neuromuscular diseases and disorders, cancer, heart diseases and disorders, and brain diseases and disorders; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Medicinal preparations for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2022-07-04 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 